



Innovation in Drug Research and Development for Prevalent Chronic Diseases — A 3-Part Virtual Workshop

February 22, March 1, and March 8, 2021

Half of all Americans live with at least one chronic disease, such as heart disease, cancer, stroke, or diabetes. These and other chronic diseases are the leading cause of death and disability in the United States and are a leading driver of health care costs. Yet investment in the leading causes of death and disability, other than cancer, has not kept pace with the public health need. This virtual public workshop will provide a venue for stakeholders to examine bottlenecks to innovation in drug research and development (R&D) for prevalent chronic diseases and highlight opportunities for spurring drug R&D in this space.

The virtual workshop will be conducted in three parts:

- Part One (February 22, 2021) discussed key opportunities and challenges for increasing investment, broadening biospecimen collection and registry use, and supporting innovative discovery and preclinical research in prevalent chronic diseases.
- Part Two (March 1, 2021) considered key aspects and opportunities related to development, translation, regulation, and support for innovative clinical research in prevalent chronic diseases.
- Part Three (March 8, 2021) will consider case studies in both discovery and clinical research related to prevalent chronic diseases, and discuss potential cross-cutting applications for other prevalent chronic diseases.

For additional information on this virtual workshop, please visit [the main project page](#).

Part 3: March 8, 2021

Case Studies in Prevalent Chronic Disease Research

11:00 a.m. **Welcome and Opening Remarks**

CARLOS GARNER, *Workshop Co-chair*
Vice President, Global Regulatory Affairs
Eli Lilly and Company

ANANTHA SHEKHAR, *Workshop Co-chair*
Senior Vice Chancellor for Health Sciences and Dean of the School of Medicine
University of Pittsburgh

SESSION I Case Studies Across the R&D Lifecycle: Mobilizing Communities and Resources, Analyzing Past Success

Session Objectives:

- Consider lessons learned in research across the R&D lifecycle in several disease areas that could have cross-cutting applications for many prevalent chronic diseases.
 - Discuss how research and patient communities have been mobilized to address discovering treatments for some example diseases, and how those approaches led to success.
 - Discuss examples of successful development for prevalent chronic disease treatments and what aspects of those approaches led to success.
- Discuss potential strategies to spur drug R&D innovation for prevalent chronic diseases.

11:10 am **Introduction and overview**

GRACE COLÓN, *Moderator*
Chief Executive Officer
InCarda Therapeutics

11:20 am **Success story from cystic fibrosis**

ROBERT K. COUGHLIN
Managing Director, Life Sciences, JLL
Former President & CEO, MassBio

11:35 am **Digital innovation for treating prevalent chronic diseases**

RAOLAT ABDULAI
Global Clinical Lead, Immunology & Inflammation
Sanofi

11:50 am **Investing in one treatment, applying to multiple diseases**

ROBERT HEINE
Distinguished Lilly Scholar
Eli Lilly and Company

12:05 pm **Moderated Panel Discussion and Audience Q&A**

Discussion Questions:

- *How can patient advocacy affect drug research and development?*
- *What can we learn from these examples about psychiatric disorders, cardiology, or other prevalent chronic diseases?*
- *How might success be replicated, and what might the investment look like for other prevalent chronic disease areas?*
- *What options exist for trials examining multiple indications?*
- *How might these successes be replicated or apply in the future, and what might the investment look like for other prevalent chronic disease areas?*
- *How have digital advancements changed approaches to developing treatments for prevalent chronic diseases, and how might they affect development in the future?*

12:45 pm **BREAK** (30 mins)

SESSION II Recap and Potential Future Strategies

Session Objectives:

- Reflect on approaches and potential strategies to spur drug R&D innovation for prevalent chronic diseases
- Brainstorm potential strategies to spur drug R&D innovation for prevalent chronic diseases (i.e., highlight promising avenues forward that merit additional time, effort, funding, or attention).

1:15 pm **Summary presentations by session moderators** (10 mins each)

GRACE COLÓN
Chief Executive Officer
InCarda Therapeutics

BETTINA DRAKE
Professor, Washington School of Medicine
Associate Director of Community Outreach and Engagement
Alvin J. Siteman Cancer Center

HOWARD B. ROSEN
Managing Director, BonVelo Ventures
Lecturer, Stanford University

SUSAN SCHAEFFER
President and Chief Executive Officer
The Patients' Academy for Research Advocacy

1:55 pm **Moderated Panel Discussion and Audience Q&A**

Discussion Questions:

- *Are there common characteristics of disease areas routinely more affected than others by either discovery and preclinical or clinical stage research barriers?*
- *What cross-cutting strategies could enable investment?*
- *How might overall risk for stakeholders innovating in prevalent chronic disease treatments be lowered, with an eye toward integrating policy with stimulus?*

2:50 pm

Closing Remarks

CARLOS GARNER, *Workshop Co-chair*
Vice President, Global Regulatory Affairs
Eli Lilly and Company

ANANTHA SHEKHAR, *Workshop Co-chair*
Senior Vice Chancellor for Health Sciences and Dean of the School of Medicine
University of Pittsburgh

3:00 pm

ADJOURN